Labcorp (LH) EVP Jonathan Meltzer sells shares and receives new equity grants

Rhea-AI Filing Summary

Labcorp Holdings Inc. executive Jonathan C. Meltzer reported multiple equity transactions. On February 10, 2026, he sold 91 shares of Labcorp common stock in an open-market transaction at $276.79 per share under a pre-arranged Rule 10b5-1 trading plan, leaving him with 2,696.3256 shares held directly.

On the same date, he was granted 1,900 non-qualified stock options with an exercise price of $284.50, vesting in three equal annual installments starting February 10, 2027 and expiring on February 9, 2036. He also received 620 restricted stock units, which vest in three equal annual installments beginning February 10, 2027, bringing his directly held RSUs to 2,937 units, each representing one share of Labcorp common stock.

Insider Trade Summary

Net Seller: 91 shares ($25,188)

Net Sell 3 txns

Insider Meltzer Jonathan C

Role EVP, Operations

Sold 91 shs ($25K)

Type	Security	Shares	Price	Value
Grant/Award	Non-qualified Stock Options	1,900	$0.00	--
Grant/Award	Restricted Stock Unit	620	$0.00	--
Sale	Common Stock	91	$276.79	$25K

Holdings After Transaction: Non-qualified Stock Options — 1,900 shares (Direct); Restricted Stock Unit — 2,937 shares (Direct); Common Stock — 2,696.326 shares (Direct)

Footnotes (1)

1. Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan. The option vests in three equal annual installments beginning on the date reflected in this column. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Meltzer Jonathan C

(Last) (First) (Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON NC 27215

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Operations

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		S(1)		91	D	$276.79	2,696.3256	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-qualified Stock Options(2)	$284.5	02/10/2026		A		1,900		02/10/2027(3)	02/09/2036	Common Stock	1,900	$0	1,900	D
Restricted Stock Unit	(4)	02/10/2026		A		620		(5)	(5)	Common Stock	620	$0	2,937(6)	D

Explanation of Responses:

1. Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

2. Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan.

3. The option vests in three equal annual installments beginning on the date reflected in this column.

4. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

5. The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027.

6. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

	/s/ Kathryn W. Kyle, Attorney-in-Fact for Jonathan C. Meltzer	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Labcorp (LH) EVP Jonathan C. Meltzer report?

Jonathan C. Meltzer reported three transactions on February 10, 2026: an open-market sale of 91 Labcorp common shares, a grant of 1,900 non-qualified stock options, and an award of 620 restricted stock units, all held directly in his name.

At what price did Labcorp (LH) executive Jonathan C. Meltzer sell shares?

He sold 91 Labcorp common shares at $276.79 per share. The transaction was executed under a Rule 10b5-1 trading plan, leaving him with 2,696.3256 common shares directly owned after the sale was completed.

What stock options were granted to Labcorp (LH) EVP Jonathan C. Meltzer?

He received 1,900 non-qualified stock options with a $284.50 exercise price. These options vest in three equal annual installments starting February 10, 2027, and expire on February 9, 2036, and are held as direct ownership.

What restricted stock units did Labcorp (LH) grant Jonathan C. Meltzer?

Labcorp granted 620 restricted stock units to Jonathan C. Meltzer. Each unit represents one share of common stock and vests in three equal annual installments beginning February 10, 2027, bringing his total RSU holdings to 2,937 units.

Were Labcorp (LH) insider sales by Jonathan C. Meltzer under a trading plan?

Yes. The sale of 91 Labcorp common shares by Jonathan C. Meltzer was made pursuant to a Rule 10b5-1 trading plan, which allows pre-arranged, systematic sales according to pre-set instructions regardless of subsequent market conditions.

How many Labcorp (LH) common shares does Jonathan C. Meltzer own after the reported sale?

After selling 91 shares, Jonathan C. Meltzer directly owns 2,696.3256 Labcorp common shares. This figure reflects his remaining beneficially owned non-derivative shares following the February 10, 2026 open-market transaction.